Second, pregabalin has already been approved for other clinical indications, potentially enabling an easier translation into clinical trials and adding to the repertoire of drug-repurposing candidates for this indication.4,18 Third, pregabalin has also been shown to have beneficial effects on axon regeneration in preclinical and clinical spinal cord injury trials,9,19 in which thrombospondin-1 is also highly expressed in the glial scar,20 indicating utilization beyond stroke therapy. The gene discussed is THBS1; the disease is Stroke.